



Contacts: Tularik Inc.
Alicia Williams (Investors/Media), 650-825-7322

Tularik to Webcast Conference Call on Full Year 2003 Financial Results

South San Francisco, Calif. –(Business Wire) – January 21, 2004-- Tularik Inc. (Nasdaq:TLRK) will host a live webcast of its conference call discussing the Company's 2003 full year financial results at 8:30 a.m. Eastern Time on January 29, 2004. The call will be hosted by David V. Goeddel, Ph.D., Chief Executive Officer. Tularik will issue a press release regarding the 2003 full year financial results before the market opens on January 29, 2004.

The press release and the live webcast can be accessed by visiting Tularik's Internet website at www.tularik.com under the "Investors/Media" tab. Following the webcast, an archived version of the call will be available at the same address for five days.

About Tularik

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. The Company currently has four drug candidates in clinical trials. Tularik is currently conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma (HCC) and Phase 2 trials with T607 for the treatment of gastric and esophageal cancer. T487, for the treatment of psoriasis, and T131, for the treatment of type 2 diabetes, are in Phase 2 trials. T487 for the treatment of rheumatoid arthritis is moving into a Phase 2 trial. T71 for the treatment of obesity is moving into Phase 1 trials. For more information, visit Tularik's Internet website at www.tularik.com.